Related Experiment Videos
A multiple modality approach combining the effect of conditioning with adoptive chemoimmunotherapy
V K Ghanta1, N S Hiramoto, S J Soong
1Department of Biology, University of Alabama, Birmingham 35294.
The International Journal of Neuroscience
|July 1, 1993
Summary
Adoptive chemoimmunotherapy (ACIT) can regress established YC8 lymphoma in mice. Combining conditioning with ACIT enhances treatment effectiveness, potentially via cytotoxic T-lymphocytes.
Area of Science:
- Immunology
- Cancer Research
- Tumor Immunology
Background:
- Pre-immunization with DBA/2 spleen cells confers protection against YC8 lymphoma in mice.
- DBA/2 spleen cells share minor histocompatibility determinants with the YC8 tumor.
- Tumor-specific vaccines increase survival but show limited regression/cure once tumors are established.
Purpose of the Study:
- To evaluate the efficacy of adoptive chemoimmunotherapy (ACIT) in regressing established YC8 lymphoma.
- To investigate the potential of combining conditioning with ACIT to enhance treatment effectiveness.
- To explore the immunological mechanisms underlying conditioned resistance.
Main Methods:
- Utilizing a mouse model of YC8 lymphoma.
- Administering adoptive chemoimmunotherapy (ACIT).
- Implementing conditioning protocols in conjunction with ACIT.
Main Results:
- ACIT demonstrated the ability to regress tumors in mice with a significant tumor burden.
- Combining conditioning with ACIT showed enhanced treatment effectiveness compared to ACIT alone.
- Conditioned resistance may involve the induction of cytotoxic T-lymphocytes.
Conclusions:
- Adoptive chemoimmunotherapy (ACIT) is a viable strategy for regressing established YC8 lymphoma.
- Conditioning enhances ACIT efficacy, suggesting a synergistic effect in cancer treatment.
- Cytotoxic T-lymphocytes are implicated as a key component of the immune response in this model.